Neuroimaging analyses from a randomized, controlled study to evaluate plasma exchange with albumin replacement in mild-to-moderate Alzheimer’s disease: additional results from the AMBAR study
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1619-7089
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Neuroimaging analyses from a randomized, controlled study to evaluate plasma exchange with albumin replacement in mild-to-moderate Alzheimer’s disease: additional results from the AMBAR study ; day:22 ; month:7 ; year:2022 ; pages:1-12
European journal of nuclear medicine and molecular imaging ; (22.7.2022), 1-12
- Urheber
-
Cuberas-Borrós, Gemma
Roca, Isabel
Castell-Conesa, Joan
Núñez, Laura
Boada, Mercè
López, Oscar L.
Grifols, Carlota
Barceló, Miquel
Pareto, Deborah
Páez, Antonio
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s00259-022-05915-5
- URN
-
urn:nbn:de:101:1-2022100319205275801003
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:32 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Cuberas-Borrós, Gemma
- Roca, Isabel
- Castell-Conesa, Joan
- Núñez, Laura
- Boada, Mercè
- López, Oscar L.
- Grifols, Carlota
- Barceló, Miquel
- Pareto, Deborah
- Páez, Antonio
- SpringerLink (Online service)
Ähnliche Objekte (12)
Dysphagia is closely related to frailty in mild-to-moderate Alzheimer’s disease
Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial
Correction: Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial
Estimating attrition in mild-to-moderate Alzheimer’s disease and mild cognitive impairment clinical trials
A 12-month randomised pilot trial of the Alzheimer’s and music therapy study: a feasibility assessment of music therapy and physical activity in patients with mild-to-moderate Alzheimer’s disease
NeuroEPO plus (NeuralCIM®) in mild-to-moderate Alzheimer’s clinical syndrome: the ATHENEA randomized clinical trial
Molecular Dynamics Simulation: Applications from Alzheimer’s Disease to Photopharmacology
Alzheimer’s disease prevention: from risk factors to early intervention
Cellular senescence in Alzheimer’s disease: from physiology to pathology
Effectiveness of the 10 cm2 Rivastigmine Patch in Taiwanese Patients with Mild-to-Moderate Alzheimer’s Dementia: A 48-Week Real-World Observational Study
Alzheimer disease : from molecular biology to therapy
Cohort Effects in Alzheimer’s Disease Trials: An Empirical Assessment Utilizing Data from the Alzheimer’s Disease Cooperative Study
Dysphagia is closely related to frailty in mild-to-moderate Alzheimer’s disease
Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial
Correction: Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial
Estimating attrition in mild-to-moderate Alzheimer’s disease and mild cognitive impairment clinical trials
A 12-month randomised pilot trial of the Alzheimer’s and music therapy study: a feasibility assessment of music therapy and physical activity in patients with mild-to-moderate Alzheimer’s disease
NeuroEPO plus (NeuralCIM®) in mild-to-moderate Alzheimer’s clinical syndrome: the ATHENEA randomized clinical trial
Molecular Dynamics Simulation: Applications from Alzheimer’s Disease to Photopharmacology
Alzheimer’s disease prevention: from risk factors to early intervention
Cellular senescence in Alzheimer’s disease: from physiology to pathology
Effectiveness of the 10 cm2 Rivastigmine Patch in Taiwanese Patients with Mild-to-Moderate Alzheimer’s Dementia: A 48-Week Real-World Observational Study
Alzheimer disease : from molecular biology to therapy
Cohort Effects in Alzheimer’s Disease Trials: An Empirical Assessment Utilizing Data from the Alzheimer’s Disease Cooperative Study
Dysphagia is closely related to frailty in mild-to-moderate Alzheimer’s disease
Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial
Correction: Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial
Estimating attrition in mild-to-moderate Alzheimer’s disease and mild cognitive impairment clinical trials
A 12-month randomised pilot trial of the Alzheimer’s and music therapy study: a feasibility assessment of music therapy and physical activity in patients with mild-to-moderate Alzheimer’s disease
NeuroEPO plus (NeuralCIM®) in mild-to-moderate Alzheimer’s clinical syndrome: the ATHENEA randomized clinical trial
Molecular Dynamics Simulation: Applications from Alzheimer’s Disease to Photopharmacology
Alzheimer’s disease prevention: from risk factors to early intervention
Cellular senescence in Alzheimer’s disease: from physiology to pathology
Effectiveness of the 10 cm2 Rivastigmine Patch in Taiwanese Patients with Mild-to-Moderate Alzheimer’s Dementia: A 48-Week Real-World Observational Study
Alzheimer disease : from molecular biology to therapy